Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Norarecoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.96 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.58 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norarecoline SCHEMBL3019132 | 0.98 | CHRM3 (1.00) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| Norarecoline SCHEMBL8872254 | 0.96 | CHRM3 (0.96) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| Norarecoline SCHEMBL29138411 | 0.95 | CHRM3 (0.93) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| Hydrochloric Acid SCHEMBL7923304 | 0.81 | CHRM3 (0.65) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| SCHEMBL6222833 | 0.79 | CHRM3 (0.67) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| SCHEMBL9499237 | 0.76 | — | — | |
| Guvacine SCHEMBL1057880 | 0.76 | BLM (1.00) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| SCHEMBL9569044 | 0.76 | TSHR (0.72) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| Hydrochloric Acid SCHEMBL5245635 | 0.75 | BLM (0.68) | CHRM3BLMTSHRSLC6A1SLC6A13 | |
| Guvacine SCHEMBL336053 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118576681-B | Liver protecting composition and preparation method thereof | 深圳市安美信生物医药科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118576681-A | Liver protecting composition and preparation method thereof | 深圳市安美信生物医药科技有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117137986-A | Betel nut extract for preventing and treating coccidiosis and application thereof | 湖南九安禾生物科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117064968-A | Preparation method and application of betel nut total alkaloids | 湖南九安禾生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20100190764-A1 | Novel compounds | GLAXO GROUP LIMITED | 2010-07-29 | — | — | US | disclosed |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | LES LABORATOIRES SERVIER (FR) | 2009-10-15 | — | — | US | disclosed |
| US-7595327-B2 | Exo-N-Hydroxy-3-[methyl({4-[(2-methylquinolin-4-yl) methoxy]phenyl}sulfonyl)amino]bicyclo[2.2.1]heptane-2-carboxamide; rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, psoriasis, osteoarthritis, tumor metastasis, sepsis, AIDS, ulcerative colitis, multiple sclerosis | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-09-21 | — | — | US | disclosed |
| US-6174898-B1 | TREATING FILARIAE IN LYMPHATIC SYSTEM BY ADMINISTERING N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF N-SUBSTITUENT AND SALTS | NOVO NORDISK A/S (DK) | 2001-01-16 | — | — | US | disclosed |
| EP-0374801-B1 | Novel N-sustituted azaheterocyclic carboxylic acids | NOVO NORDISK AS (DK) | 1997-03-19 | — | — | EP | disclosed |
| US-5214057-A | Used as analgesic, anxiolytic, antidepressant, hypnotic and for treating epilepsy and muscular disorder | NOVO NORDISK A/S (DK) | 1993-05-25 | — | — | US | disclosed |
| US-5071859-A | Analgesic, antianxiolytic, antiepileptic, antidepressant; gammaa-aminobutyric acid inhibitor | NOVO NORDISK A/S, A CORP. OF DENMARK (DK) | 1991-12-10 | — | — | US | disclosed |
| EP-0374801-A2 | Novel N-sustituted azaheterocyclic carboxylic acids | NOVO NORDISK A/S (DK) | 1990-06-27 | — | — | EP | disclosed |
| EP-0066456-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND THEIR ESTERS | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4383999-A | GAMMA-AMINOBUTYRIC ACID SEDATIVES, ANALGESTICS, ANTIEPILEPTIC, MUSCULAR AND PSYCHOLOGICAL DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1983-05-17 | — | — | US | disclosed |
| EP-0011447-B1 | BLOOD PLATELET AGGREGATION INHIBITORY 1-BENZYL-1,2,5,6-TETRAHYDROPYRIDINE-3-CARBOXYLIC ACID DERIVATIVES AND SALTS THEREOF; PHARMACEUTICAL COMPOSITIONS THEREOF; AND ANALOGY PROCESSES FOR THE MANUFACTURE THEREOF | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-01-05 | — | — | EP | disclosed |
| EP-0066456-A1 | N-substituted azaheterocyclic carboxylic acids and their esters | SMITHKLINE BECKMAN CORPORATION (US) | 1982-12-08 | — | — | EP | disclosed |
| US-4238488-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-12-09 | — | — | US | disclosed |
| EP-0011447-A1 | Blood platelet aggregation inhibitory 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivatives and salts thereof; pharmaceutical compositions thereof; and analogy processes for the manufacture thereof | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | SI, MMP12, TNF | CHRM3 3909/4885SLC6A1 4510/4885CHRM2 2768/4885 |
| US-20100190764-A1 | Novel compounds | HCRTR1, HCRTR2, CNR1 | CHRM3 593/4885SLC6A1 20/4885CHRM2 808/4885 |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | IDO1, AHR, IDO2 | CHRM3 246/4885SLC6A1 945/4885CHRM2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.